Three Years Sustained Complete Remission Achieved in a Primary Refractory ALK-Positive Anaplastic T Large Cell Lymphoma Treated with Crizotinib

The prognosis of the primary refractory anaplastic lymphoma kinase (ALK+) anaplastic T large cell lymphoma is ominous. The identification of molecular targets with potential to drive oncogenesis remains a cornerstone for the designing of new selective cancer therapies. Crizotinib is a selective ATP-...

Descripción completa

Detalles Bibliográficos
Autores principales: Mahuad, Carolina Valeria, Repáraz, María de los Ángeles Vicente, Zerga, Marta E., Aizpurua, María Florencia, Casali, Claudia, Garate, Gonzalo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: PAGEPress Publications, Pavia, Italy 2016
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4935828/
https://www.ncbi.nlm.nih.gov/pubmed/27441079
http://dx.doi.org/10.4081/rt.2016.6266

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4935828/
https://www.ncbi.nlm.nih.gov/pubmed/27441079
http://dx.doi.org/10.4081/rt.2016.6266

Ejemplares similares